Speakers

Personal Information

Dr. Cohen joined MedImmune/AstraZeneca in 2014 as a Scientist in the Infectious Disease Dept(Medimmune). From 2014 to 2020 Dr. Cohen lead efforts supporting anti-bacterial antibody programs (S. aureus primarily) and co-lead efforts to mine the gut microbiome for drug and drug targets. During this time, he lead microbiome strategy for CVRM. Since 2021, Dr. Cohen has been working on the development of vaccines and antibodies for the prevention or treatment of respiratory viral infections. He led the development of the COVID-19 mAb Kavigale from the time of antibody discovery through global approvals. Currently, Taylor is Leading a number of programs in the respiratory viral disease space. Prior to joining AstraZeneca Dr. Cohen received his PhD in Bioengineering from The University of Pennsylvania after which he did a post-doc At Columbia University.